Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.

Cliniques universitaires Saint-Luc- Université Catholique de Louvain1 site in 1 country40 target enrollmentSeptember 2015

ConditionsSquamous Cell Carcinoma of the Head and Neck

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Squamous Cell Carcinoma of the Head and Neck
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Enrollment: 40
Locations: 1
Primary Endpoint: Identification of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with immunohistochemistry (KI67) on FFPE (fixation followed by paraffin embedding) slides
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to:

generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer

perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors
evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options
evaluate biomarkers of drug sensitivity
study primary and secondary (acquired) resistance in these models

Registry

clinicaltrials.gov

Start Date

September 2015

End Date

December 2025

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent
•Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available
•Follow-up data should be available
•Patients with recurrent disease are allowed
•Written informed consent

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Identification of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with immunohistochemistry (KI67) on FFPE (fixation followed by paraffin embedding) slides

Time Frame: 10 years

Identification of the biomarkers of new cancer therapies for head and neck

Secondary Outcomes

Characterization of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with genetic techniques(10 years)